Creso Pharma Secures New US$625,000 Purchase Order for Medicinal Cannabis
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Creso Pharma Limited’s (ASX:CPH;FRA:1X8) wholly-owned subsidiary Mernova Medicinal Ltd has received a US$625,000 purchase order for its premium, cured and hand-trimmed dried medicinal cannabis flower from Univo Pharmaceuticals Ltd (TLV: UNVO).
This is the second wholesale purchase order received from Univo, the first being in April, and this provides Creso with the opportunity to leverage Univo’s extensive distribution networks into the rapidly growing Israeli market.
Israel is a pioneer in the global medicinal cannabis market, which has been estimated to be worth US$62.7 billion by 2024.
Listed on the Tel Aviv Stock Exchange, Univo is a medicinal cannabis company which has licenses for the entire supply chain including cultivation, production, research and development and distribution.
As a backdrop, Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland.
The company has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.
Delivery within one month
Under the terms of the Purchase Order announced today, Mernova will ship four of its premium strains of cured, hand-trimmed, dried medicinal cannabis flower, to Univo in Israel.
An initial 25% of the order value will be paid in cash upon receipt of the export license from Health Canada, a further 25% will paid upon receipt of goods at TLV Ben Gurion Airport, and the remaining 50% of the order value will be paid within 30 business days of the goods being delivered at Univo’s factory in Israel.
Delivery is expected to be completed within one month, subject to the grant of an export permit by Health Canada.
The Purchase Order cannot be terminated by Univo, but Univo has the right to reject the product and receive a partial refund if any material defects are identified within 21 business days of delivery.
Entry into Canada imminent
Commenting on the significance of this order in terms of expanding Creso Pharma’s market presence in this high-growth area, chief executive and co-founder Dr. Miri Halperin Wernli said, “Following our initial entry into the Israeli market in April this year, we are delighted to have received another significant purchase order from Univo which further strengthens our penetration into this growing market.
“Univo has an impressive distribution network, including significant connections to pharmacies and patients in Israel, so this truly is a tremendous growth opportunity for Creso.
“Israel is widely recognised as one of the more progressive and active cannabis markets globally and Univo’s acceptance and continued demand for our cannabis is a major testament to the quality of our product and the expertise of the Mernova team.
“As wholesale demand for our products continues to solidify, we are also preparing for Mernova’s launch into the Canadian retail market which is another exciting near-term opportunity.
‘’With several value catalysts on the horizon I look forward to providing further updates from across the business in the near-term.”
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
